Medibank (ASX:MPL) share price slips as customers hit 3.7 million

What's moving the Medibank share price today?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Medibank Private Ltd (ASX: MPL) share price is moving higher this morning. This follows the release of the private health insurers' annual report for 2021.

While the financial results had already been shared with investors back on 25 August 2021, today's release comes with some added details and commentary.

At the time of writing, the Medibank Private share price is down 0.28% to $3.55 in early trade.

Let's dive into the report.

A man sitting at his dining table looks at his laptop and ponders the share price.

Image source: Getty Images

More customers getting more back

To kick things off, the report opens with an elating one-liner, stating "We grew more in the past 12 months than we have in over 10 years." Such a statement could have investors jumping for joy.

Although the exact metric being measured isn't specified, we know that it's not pertaining to the company's net earnings after tax. In FY21, Medibank's group net profit after tax increased 39.8% to $441.2 million. We only need to go back to FY16 to see earnings grow more than this. For reference, FY16 witnessed the bottom line climb 46% to $417.6 million.

Additionally, customer numbers across the Medibank and ahm brands have slipped since 2016 as well. According to its annual report at the time, the company served 3.8 million customers. Meanwhile, the company counts 3.7 million people as customers — a reduction of nearly 3%. This might be weighing on the Medibank Private share price this morning.

However, what has increased is the amount of money paid in claims to customers. For the recent financial year, Medibank coughed up $5.6 billion in claims, increasing 2% from the prior year. In fact, the company's COVID financial support package for customers was the largest in its 45-year history.

To date, Medibank has provided $300 million, with $103 million in COVID permanent net claims savings being returned in premium relief. Adding to this, CEO David Koczkar said, "We stand by our commitment not to profit from COVID and will continue to return any related permanent net claims savings to our customers."

This act of returning some of the premiums paid by customers was in recognition of the impact COVID has had on people's ability to use their health insurance.

It appears premium return helped bolster the company's brand among customers. In the year, Medibank customer advocacy rose 5.3 points to 37.1. Likewise, ahm gained 1.8 points to finish at 43.

Medibank share price wobbles on directors retirement

In addition to the annual report, Medibank also announced the retirement of two non-executive directors of its board.

According to the release, non-exec directors Christine O'Reilly and Peter Hodgett will retire from the board on 18 November 2021. This will be at the conclusion of the annual general meeting, of which, the directors have opted not to stand for re-election.

Commenting on the news, Medibank chair Mike Wilkins said:

I would like to take this opportunity to thank both Christine and Peter for their valuable contribution to our
company during their time as directors. They both joined the Board prior to Medibank's listing on the
Australian Securities Exchange and helped guide the business through its transition from government-owned business to privatised company.

The search for two new directors is already underway.

Motley Fool contributor Mitchell Lawler has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A man looking at his laptop and thinking.
Earnings Results

Cochlear posts FY26 profit at top end of guidance with new product momentum

Management is guiding to a profit rebound in FY 2027.

Read more »

Group of scientists cheering in the lab after the company received good news.
Healthcare Shares

Mesoblast shares are up sharply. Is this biotech still undervalued?

Mesoblast faces big risks, but brokers see substantial upside if successful.

Read more »

A scientist in a white coat and glasses puts her arms in the air in a sign of strength and success.
Healthcare Shares

Why is this ASX 300 healthcare stock up more than 17%?

Strong earnings have this company riding high.

Read more »

Two people comparing and analysing material.
Healthcare Shares

Could the CSL share price reach $200 in 2027?

It might sound ambitious after recent struggles, but the valuation required to get there is less demanding than you might…

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Mesoblast share price jumps on blockbuster news

It has been a good start to the week for this biotech company.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

Australian Clinical Labs delivers profit growth and stronger margins in FY26

Australian Clinical Labs’ FY26 earnings reveal profit growth and margin improvements despite market headwinds.

Read more »

medical research laboratory assistant examines solutions in test tubes
Healthcare Shares

CSL shares are rallying. Could tomorrow's results pour fuel on the fire?

One strong month isn't enough. CSL needs earnings recovery to follow.

Read more »

A man with a perplexed expression on his face scratches his head.
Healthcare Shares

4DMedical shares are up 670% — but why have they halved?

Can the company turn its commercial momentum into another explosive share-price rebound?

Read more »